Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Repligen Corp (RGEN) -- Ignore unavailable to you. Want to Upgrade?

To: Manfred Sondermann who wrote (165)	10/7/1999 10:30:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 395

Manfred....... It would take a book to answer your questions. CTLA4-Ig blocks molecules known as B7-1 and B7-2. Don't know which ABGX project you're talking about.... anti-IL-8? BTRN's antibody, if it works by the mechanism described by research from Belgium and France, is a much more targeted approach. However, I see no evidence that MEDI is testing it at concentrations that actually test this capacity. Your question is just too basic for me to proceed, and if you hone it I won't have the time to answer in any event. :-) I can only suggest that you review the IDPH, BGEN and BTRN threads in detail. There is an existing web page that might help you, but not certain that it's yet public. Rick